FDA Greenlights Arcellx’s CART-ddBCMA Treatment Trial After Clinical Hold Lifted
Washington, D.C. – Arcellx’s iMMagine-1 Phase II clinical program has received approval from the FDA to resume testing its CART-ddBCMA treatment for patients with relapsed or refractory multiple myeloma, following a temporary hold on the trial earlier this year. The company announced this development on Monday, signaling a positive step forward for the innovative cell … Read more